We at Mindpeak GmbH are very happy to announce the CE mark for our „Mindpeak Lung (NSCLC) PD-L1 (SP263) RoI“, a plug-and-play AI solution to detect and quantify PD-L1 expression within user-defined Regions of Interest (RoI) on non-small-cell lung cancer. In a study our software showed a 96.5% agreement for the most relevant scanners on the market. Mindpeak Lung PD-L1, our 7th CE marked product, is a milestone in supporting pathologists in the diagnosis of Lung Cancer, which is among the most difficult tasks for pathologists. It identifies tumorous cells and quantifies them to support TPS-scoring.
Mindpeak announces scanner agnostic CE-marked PD-L1 AI solution to support Lung Cancer Diagnosis
Related reading
Mindpeak Welcomes Christiaan Neeleman to the Board of Directors
We are delighted to announce that Christiaan Neeleman has joined Mindpeak’s Board of Directors.
With more than 20 years of international leadership experience in life sciences, diagnostics, and health technology - including senior roles at Discovery Life Sciences, Definiens, and Philips Healthcare - Christiaan brings deep expertise that will help accelerate our global expansion.
His proven track record in biomarker development, companion diagnostics, and scaling precision diagnostics businesses aligns perfectly with Mindpeak’s mission: enabling faster, more accurate cancer diagnostics through AI-powered pathology.
We are excited to collaborate with Christiaan as we strengthen partnerships, expand into new markets, and further drive the adoption of AI across clinical and research settings.
Read the full press release here
.png)
Expanding Global Access to AI Diagnostics – Our New Partnership with Pathomation
At Mindpeak, our vision is clear: world-class AI diagnostics should be available to every pathology lab, everywhere. By partnering with leading technology providers, we’re removing barriers to adoption and making AI-powered precision diagnostics a practical reality for labs worldwide.
Seamless AI Integration with Pathomation
Through our strategic collaboration with Pathomation, a globally trusted provider of digital pathology platforms, Mindpeak’s CE-IVD certified AI algorithms – including Ki-67, HER2, and zero-click PD-L1 scoring across multiple tissue types – are now natively integrated into Pathomation’s solutions.
This partnership means laboratories can:
- Adopt advanced AI instantly – No extra development, integrations, or technical overhead required.
- Work within existing workflows – Our algorithms run directly inside Pathomation’s widely adopted platform.
- Deliver faster, more consistent results – Helping pathologists make confident, high-quality diagnostic decisions for patients everywhere.
Reaching More Labs, Globally
Pathomation’s worldwide presence, with distributor networks and users spanning Europe, Asia, and Latin America, ensures that AI-powered image analysis is accessible to more labs and more patients across the globe. Together, we’re removing geographic and technical barriers to bring state-of-the-art diagnostics to every corner of the world.
“Every partnership we form moves us closer to our goal: AI-powered image analysis in every lab, for every patient. Our collaboration with Pathomation is an important step toward making this vision a reality.” – Felix Faber, CEO, Mindpeak
🔗 Learn more about the partnership and read the full press release: https://tissuepathology.com/2025/08/21/pathomation-and-mindpeak-forge-strategic-partnership-to-accelerate-ai-adoption-in-digital-pathology-workflows/
.png)
Mindpeak Joins Techcyte Fusion Partner Program to Accelerate AI-Powered Digital Pathology
Mindpeak is proud to announce its new collaboration with Techcyte, a leading provider of AI-driven digital diagnostics, by joining the Techcyte Fusion™ Partner Program. This partnership brings together two pioneers in artificial intelligence for pathology, united by a mission to enhance diagnostic accuracy, efficiency, and reproducibility in cancer research and diagnostics.
Supporting Labs with Seamless AI Integration
Mindpeak’s suite of AI tools—including Research Use Only (RUO) algorithms for breast, prostate, and gastric cancer, alongside advanced IHC marker analysis—will now be available through the Techcyte Fusion™ platform. By integrating Mindpeak’s robust, explainable AI models, labs worldwide can benefit from interoperable solutions that fit naturally into existing workflows, supporting reproducible research and streamlined daily operations.
“We built Mindpeak to support pathologists with reliable, explainable AI that integrates effortlessly into daily routines,” said Felix Faber, Founder and CEO of Mindpeak. “Partnering with Techcyte allows us to reach more labs with a shared commitment to transforming cancer diagnostics through high-quality, scalable solutions.”
A Shared Vision for the Future of Pathology
The partnership underscores a shared vision: driving the future of digital pathology through validated, workflow-based AI. As labs face growing complexity and demand, collaborations like this will play a critical role in enabling faster, more precise insights and ultimately improving patient care.
Learn More
https://www.einpresswire.com/article/830144303/mindpeak-joins-techcyte-fusion-partner-program-to-accelerate-ai-powered-digital-pathology
Ready to advance your diagnostics
Connect with our team to explore how precision pathology works in your setting